37,859 Shares in Kenvue Inc. (NYSE:KVUE) Acquired by William Allan Corp

William Allan Corp purchased a new stake in Kenvue Inc. (NYSE:KVUE) during the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 37,859 shares of the company’s stock, valued at approximately $876,000.

Other institutional investors also recently made changes to their positions in the company. Huntington National Bank boosted its holdings in Kenvue by 26.5% in the third quarter. Huntington National Bank now owns 4,161 shares of the company’s stock valued at $96,000 after acquiring an additional 871 shares during the last quarter. ING Groep NV grew its holdings in shares of Kenvue by 23.6% during the 3rd quarter. ING Groep NV now owns 3,576,616 shares of the company’s stock worth $82,727,000 after purchasing an additional 681,954 shares during the period. Lorne Steinberg Wealth Management Inc. increased its position in Kenvue by 59.0% during the 2nd quarter. Lorne Steinberg Wealth Management Inc. now owns 154,690 shares of the company’s stock worth $2,812,000 after purchasing an additional 57,375 shares in the last quarter. Kennon Green & Company LLC raised its holdings in Kenvue by 140.7% in the second quarter. Kennon Green & Company LLC now owns 159,106 shares of the company’s stock valued at $2,893,000 after buying an additional 93,008 shares during the period. Finally, Czech National Bank raised its holdings in Kenvue by 20.3% in the second quarter. Czech National Bank now owns 364,886 shares of the company’s stock valued at $6,634,000 after buying an additional 61,635 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Price Performance

KVUE stock opened at $24.13 on Friday. The stock’s 50 day moving average is $22.92 and its two-hundred day moving average is $20.96. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The company has a market capitalization of $46.26 billion, a PE ratio of 43.87, a P/E/G ratio of 2.19 and a beta of 1.36. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm had revenue of $3.90 billion for the quarter, compared to analysts’ expectations of $3.92 billion. During the same period in the prior year, the company posted $0.31 earnings per share. The firm’s quarterly revenue was down .4% on a year-over-year basis. Analysts predict that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th were given a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, November 13th. This represents a $0.82 annualized dividend and a dividend yield of 3.40%. Kenvue’s payout ratio is 149.09%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on KVUE shares. Royal Bank of Canada lowered shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price objective for the company. in a research report on Tuesday, September 24th. UBS Group increased their price target on Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. JPMorgan Chase & Co. raised their price objective on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Piper Sandler upped their target price on Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research report on Monday, September 23rd. Finally, Deutsche Bank Aktiengesellschaft raised their target price on Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $22.64.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.